Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm, Prospective, Multi-center, Tandem Two Stage Designed, Phase II Study to Evaluate the Efficacy of Fulvestrant in Women With Recurrent/Metastatic Estrogen Receptor Positive Gynecological Malignancies

NCT03926936 is registered in ClinicalTrials.gov with Frederic Amant as lead sponsor.

NCT NCT03926936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03926936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm, Prospective, Multi-center, Tandem Two Stage Designed, Phase II Study to Evaluate the Efficacy of Fulvestrant in Women With Recurrent/Metastatic Estrogen Receptor Positive Gynecological Malignancies
Lead sponsor
Frederic Amant
Phase
Phase 2
Overall status
Completed
Start date
March 13, 2019
Completion date
December 27, 2022
Enrollment
17 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

adenosarcoma of uterus, endometrial cancer, endometrial stromal sarcoma, leiomyosarcoma uterus, serous ovarian tumor, sex cord stromal tumor